Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Weighing the outcomes

The emergent healthcare value era, its consequences, and what drug firms need to do about it

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Figure 1: Growth in drug expenditures.
Figure 2
Figure 3: Biotech drugs in the oncology pipeline.


  1. IMS Health. IMS Health Reports Global Pharmaceutical Market Grew 7.0 Percent in 2006, to $643 Billion (IMS, Norwalk, CT, USA, March 20, 2007). articleC/0,2777,6599_3665_80560241,00.html

Download references

Author information

Authors and Affiliations


Ethics declarations

Competing interests

CardioVascular BioTherapeutics is a client of the Bruckner Group.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Russo, M., Balekdjian, D. Weighing the outcomes. Nat Biotechnol 26, 173–182 (2008).

Download citation

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing